Efficacy and safety of Camrelizumab combined with Apatinib in the treatment of advanced gastric cancer
Objective To observe the clinical efficacy and safety of Camrelizumab combined with Apatinib in the treatment of advanced gastric cancer.Methods A total of 46 patients with advanced gastric cancer admitted to Jiujiang NO.1 People's Hospital from June 2020 to December 2021 were selected as research objects,and they were divided into observation group and control group according to random number table method,with 23 cases in each group.The observation group was treated with Camrelizumab combined with Apatinib,while the control group was treated with Apatinib monotherapy every 21 days for 12 consecutive courses.Progression-free survival(PFS),overall survival(OS),clinical efficacy,quality of life and inci-dence of adverse reactions were compared between the two groups.Results PFS and OS in observation group were higher than those in control group,the differences were statistically significant(P＜0.05).There were no significant differences in objective response rate(ORR)and disease control rate(DCR)between the two groups(P＞0.05).After 3,6,9 and 12 treat-ment courses,the Karnofsky performance status(KPS)scores of two groups were higher than those before treatment,the dif-ferences were statistically significant(P＜0.05).After 6,9 and 12 treatment courses,the KPS scores of observation group were higher than those of control group,and the differences were statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Camrelizumab com-bined with Apatinib is effective in the treatment of ad-vanced gastric cancer with chemotherapy failure,which can inhibit the progression of tumor,prolong the survival period of patients,improve the quality of life of patients,and have little toxic side effects.
Gastric cancerCamrelizumabApatinibClinical efficacyQuality of life
万方数据
维普
